Are Allergic Diseases a Risk Factor for Systemic Side Effects After COVID-19 Vaccines?
Journal Title: Journal of European Internal Medicine Professionals (JEIMP) - Year 2024, Vol 2, Issue 1
Abstract
Background: In clinical trials of currently-approved COVID-19 vaccines, patients with a known allergy or a history of anaphylaxis were excluded from the studies. This situation creates doubts about the risk and type of side effects of COVID-19 vaccines in patients with allergic diseases. Therefore, we aimed to evaluate local side effects (LSE) and systemic side effects (SSE) after COVID-19 vaccines in patients with allergic diseases and to determine possible risk factors. Methods: Between April 1, 2021 and September 30, 2021, 648 adult patients who received any COVID-19 vaccines were included in this case-control retrospective study. Results: Six hundred forty-eight adult patients [Female: 446 (68.8%), Male: 202 (32.2%)] participated in the study. After the 1st dose of COVID-19 vaccine, 24.1% of patients reported SSE. After the 2nd dose of COVID-19 vaccines, 67 patients (12.3%) developed SSE. Female gender (OR: 1.757, 95%Cl: 1.143-2.702, p: 0.010), history of previous COVID-19 infection (OR: 1.762, 95%Cl: 1.068-2.906, p: 0.026), and COVID-19 vaccine type administered (OR: 4.443, 95% CI: 2.640-7.476, p<0.001) were found to be independent risk factors for SSE after COVID-19 vaccines. Premedication (OR: 0.454, 95% Cl: 0.281-0.733, p<0.001), was found to be a protective factor for SSE developing after COVID-19 vaccines. Conclusion: Systemic side effects against CoronaVac and Pfizer-BioNTech COVID-19 vaccines are very low. Patients with allergic disease do not have an increased risk for SSE that may develop after COVID-19 vaccines. Moreover, doubts or fears about possible side effects in the allergic patient group should not be an obstacle to COVID-19 vaccination.
Authors and Affiliations
Emel Atayık Konya City Hospital, Department of Allergy and Clinical Immunology, Konya, Turkey https://orcid.org/0000-0002-7011-7752 Gökhan Aytekin Konya City Hospital, Department of Allergy and Clinical Immunology, Konya, Turkey https://orcid.org/0000-0002-9089-5914 Hakan Özer Konya City Hospital, Department of Nephrology, Konya, Turkey https://orcid. org/0000-0001-9174-0351
Keywords
Related Articles
- EP ID EP751145
- DOI https://doi.org/10.5281/zenodo.10656636
- Views 28
- Downloads 0
Dyslipidemia and Kidney: An Updated View
Dyslipidemia is a common concern in various kidney-related conditions, including chronic kidney disease, nephrotic syndrome, kidney transplant patients, and those undergoing dialysis. Dyslipidemia is a significant risk f...
The Other Side of The Coin in Assisted Peritoneal Dialysis
Background: Assisted peritoneal dialysis (aPD) has long been used worldwide to treat elderly and frail patients with end-stage renal disease. In developed countries, aPD is provided by health professionals, while in dev...
Can the Monocyte/HDL Ratio be used as A Marker to Predict Fatty Liver and Its Stages?
Background: Our study aims to determine whether the monocyte/HDL ratio is a marker that can be used to predict the presence and stage of non-alcoholic fatty liver. Material and Method: Patients aged 18-65 years withou...
The Effect of Hot Pepper, Sumac, and Chewing on Gastric inhibitory peptide, Glucagon-like Peptide, and Cholecystokinin Hormone Secretion
Background: The influence of various dietary factors on metabolic responses and gastrointestinal function has been the subject of extensive research. In this study, we aimed to investigate the effects of capsaicin, chewi...
Acute Pancreatitis After a Late Period of Metformin Intoxication in a Non-Diabetic Patient
Metformin, an oral antidiabetic drug, is the first-line treatment modality for the treatment of non-insulin-dependent diabetes mellitus. Metformin is more commonly associated with gastrointestinal side effects. Acute pan...